Aspirin-like_JJ
drugs_NNS
can_MD
protect_VB
human_JJ
T_NN
lymphocytes_NNS
against_IN
benzoquinone_NN
cytotoxicity_NN
:_:
evidence_NN
for_IN
a_DT
NAD_NN
-LRB-_-LRB-
P_NN
-RRB-_-RRB-
H_NN
:_:
quinone_NN
reductase-dependent_JJ
mechanism_NN
._.

Benzene_NN
toxicity_NN
towards_IN
lymphocytes_NNS
is_VBZ
thought_VBN
to_TO
be_VB
mediated_VBN
by_IN
metabolites_NNS
of_IN
benzene_NN
including_VBG
benzoquinone_NN
-LRB-_-LRB-
BQ_NN
-RRB-_-RRB-
._.

NAD_NN
-LRB-_-LRB-
P_NN
-RRB-_-RRB-
H_NN
:_:
quinone_NN
reductase_NN
-LRB-_-LRB-
QR_NN
-RRB-_-RRB-
is_VBZ
known_VBN
to_TO
protect_VB
against_IN
BQ_NN
toxicity_NN
._.

The_DT
expression_NN
of_IN
the_DT
QR_NN
gene_NN
is_VBZ
regulated_VBN
by_IN
the_DT
transcription_NN
factor_NN
AP-1_NN
._.

We_PRP
had_VBD
previously_RB
found_VBN
that_IN
aspirin-like_JJ
drugs_NNS
-LRB-_-LRB-
ALD_NN
-RRB-_-RRB-
induce_VBP
AP-1_NN
in_IN
human_JJ
T_NN
lymphocytes_NNS
._.

It_PRP
was_VBD
therefore_RB
hypothesized_VBN
that_IN
ALD_NN
would_MD
protect_VB
lymphocytes_NNS
against_IN
BQ_NN
toxicity_NN
by_IN
inducing_VBG
QR_NN
._.

Molt-4_NN
cells_NNS
-LRB-_-LRB-
M4_NN
-RRB-_-RRB-
,_,
a_DT
human_JJ
T_NN
lymphocyte_NN
cell_NN
line_NN
,_,
were_VBD
incubated_VBN
with_IN
different_JJ
concentrations_NNS
of_IN
two_CD
ALD_NN
,_,
flurbiprofen_NN
and_CC
sodium_NN
diclofenac_NN
,_,
and_CC
then_RB
exposed_VBN
to_TO
BQ_NN
._.

Toxicity_NN
was_VBD
measured_VBN
by_IN
viability_NN
-LRB-_-LRB-
trypan_NN
blue_JJ
exclusion_NN
-RRB-_-RRB-
._.

Both_DT
drugs_NNS
protected_VBD
the_DT
cells_NNS
against_IN
BQ_NN
cytotoxicity_NN
in_IN
a_DT
dose-dependent_JJ
manner_NN
,_,
e.g._FW
,_,
sodium_NN
diclofenac_NN
at_IN
15_CD
microM_NN
reduced_VBD
the_DT
fraction_NN
of_IN
BQ-treated_JJ
dead_JJ
cells_NNS
by_IN
70_CD
%_NN
._.

ALDs_NNS
induced_VBD
QR_NN
activity_NN
in_IN
the_DT
M4_NN
cells_NNS
in_IN
the_DT
same_JJ
range_NN
of_IN
concentrations_NNS
that_WDT
protected_VBD
the_DT
cells_NNS
against_IN
BQ_NN
toxicity_NN
._.

The_DT
protective_JJ
effect_NN
of_IN
ALD_NN
was_VBD
significantly_RB
reduced_VBN
by_IN
dicoumarol_NN
,_,
a_DT
QR-specific_JJ
inhibitor_NN
._.

Since_IN
human_JJ
T_NN
cells_NNS
and_CC
T_NN
cell_NN
lines_NNS
do_VBP
not_RB
metabolize_VB
arachidonic_JJ
acid_NN
,_,
our_PRP$
data_NNS
suggest_VBP
that_IN
ALD_NN
can_MD
protect_VB
human_JJ
T_NN
lymphocytes_NNS
against_IN
a_DT
metabolite_NN
of_IN
benzene_NN
by_IN
induction_NN
of_IN
QR_NN
activity_NN
._.

